Mirvetuximab soravtansine dosing weight considerations

Abstract

Get full access to this article

View all access options for this article.

References

Smith

Medina

Miao

, et al. A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer. Am J Health Syst Pharm 2025; 82: 522–536. PMID: 40126684; PMCID: PMC12094874.

Elahere (mirvetuximab soravtansine injection) package insert . IMMUNOGEN INC. 03/22/2024.

Center for Drug Evaluation and Research, Food and Drug Administration . Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products—Content and Format Guidance for Industry. Food and Drug Administration; 2023. www.fda.gov/media/72142/download (accessed 07/08/2025).

Food and Drug Administration, Department of Health and Human Services . Dosage and Administration. Prescribing Information. 21 CFR 201.57 (c)(3) URL: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.57#p-201.57(c)(3). (Accessed 07/30/2025).

Lagraauw

Method

, et al. Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: justification of therapeutic dose regimen. Br J Clin Pharmacol 2025 Jan; 91: 220–231. Epub 2024 Sep 22. PMID: 39307840.

Moore

Borghaei

Malley

, et al. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 2017; 123: 3080–3087. Epub 2017 Apr 25. PMID: 28440955; PMCID: PMC6896318.

Hanze

Zhu

, et al. Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: the antibody-drug conjugate, payload and metabolite. Br J Clin Pharmacol 2024 Feb; 90: 568–581. Epub 2023 Nov 13. PMID: 37872122.

Chichester

Holmes

Hubbard

. Ideal body weight: a commentary. Clin Nutr ESPEN 2021 Dec; 46: 246–250. Epub 2021 Oct 12. PMID: 34857204; PMCID: PMC8646317.

Pai

Paloucek

. The origin of the “ideal” body weight equations. Ann Pharmacother 2000 Sep; 34: 1066–1069. PMID: 10981254.

10.

Field

Kosmider

Jefford

, et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey. J Oncol Pract 2008; 4: 108–113. PMID: 20856612; PMCID: PMC2794002.

11.

Fahrenbruch

Kintzel

Bott

, et al. Dose rounding of biologic and cytotoxic anticancer agents: a position statement of the hematology/oncology pharmacy association. J Oncol Pract 2018 Mar; 14: e130–e136. Epub 2018 Feb 5. PMID: 29400987.

12.

Dilawari

Shah

Ison

, et al. FDA Approval summary: mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant ovarian cancer. Clin Cancer Res 2023 Oct 2; 29: 3835–3840. PMID: 37212825; PMCID: PMC10592645.

13.

Berton

Bettonte

Stader

, et al. Repository describing the anatomical, physiological, and biological changes in an obese population to inform physiologically based pharmacokinetic models. Clin Pharmacokinet 2022 Sep; 61: 1251–1270. Epub 2022 Jun 14. PMID: 35699913; PMCID: PMC9439993.

14.

Pai

. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012 Sep; 32: 856–868. Epub 2012 Jun 18. PMID: 22711238.

15.

Bossi

Delrio

Mascheroni

, et al. The Spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review. Nutrients 2021 Jun 9; 13: 1980. PMID: 34207529; PMCID: PMC8226689.

16.

Ledermann

Canevari

Thigpen

. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol 2015 Oct; 26: 2034–2043. Epub 2015 Jun 10. PMID: 26063635.

17.

Cahill

Cleary

Cullinan

. The influence of electronic health record design on usability and medication safety: systematic review. BMC Health Serv Res 2025 Jan 6; 25: 31. PMID: 39762805; PMCID: PMC11705737.